Most patients with diabetic retinopathy who take the GLP-1 agonist semaglutide don t experience a worsening of the condition, a new study found, but they still require screening and follow-up.
Recalled in 2022, a port delivery system for ranibizumab to treat wet AMD demonstrated that vision and retinal anatomy remained stable in patients who had the device for 5 years.
While a Korean study shows reduction in diabetic retinopathy progression by 11% with fenofibrate plus statin compared with statin alone, some reservations remain over wider use.